CN100558387C - The Chinese medicinal capsule of treatment heart failure - Google Patents
The Chinese medicinal capsule of treatment heart failure Download PDFInfo
- Publication number
- CN100558387C CN100558387C CNB2007100131188A CN200710013118A CN100558387C CN 100558387 C CN100558387 C CN 100558387C CN B2007100131188 A CNB2007100131188 A CN B2007100131188A CN 200710013118 A CN200710013118 A CN 200710013118A CN 100558387 C CN100558387 C CN 100558387C
- Authority
- CN
- China
- Prior art keywords
- parts
- heart failure
- radix
- chinese medicinal
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Abstract
The invention discloses a kind of Chinese medicinal capsule for the treatment of heart failure.Problems such as it has solved the Chinese medicine cost height of present treatment heart failure, and effect is general, and toxic and side effects is strong, it is low to have a cost, advantage such as toxic and side effects is little, and therapeutic effect is good.Its prescription is, the weight portion of each composition is, LISHEN 5-7 part, Fructus Schisandrae Chinensis 2-4 part, Radix Ophiopogonis 11-13 part, Radix Notoginseng 2-4 part, Radix Aconiti Lateralis Preparata 2-4 part, Herba Leonuri 14-16 part, mentioned component is pulverized last, crosses 200 mesh sieves, goes into capsule.
Description
Technical field
The present invention relates to a kind of medicine for the treatment of heart failure, relate in particular to a kind of Chinese medicinal capsule for the treatment of heart failure.
Background technology
Heart failure is a kind of clinical syndrome of complexity, is the various cardiopathic serious stages.Can be divided into systolic heart failure and diastolic heart failure by its evolution.Because the aging of population, the heart infarction success of infusion therapy again makes old heart failure raise day by day, and 50-59 year heart failure sickness rate 10% according to statistics, and 〉=80 years old up to 10%, in the 50-89 crowd in year, age increases by 10 years old, and its prevalence raises 1 times, and the old people accounts for 75% of heart failure sum, 5 annual survival rates of old people's heart failure are 25%-50% at present, and old heart failure is correctly discerned and handled to 5 times of incidence rates of sudden death how to the general population, and reducing sickness rate and mortality rate is a great medical problem.Though have the medicine of various types of treatment heart failures to occur at present, there is the cost height in it, curative effect is general, and toxic and side effects is strong, and health is had harmful effect, should not take for a long time.
Summary of the invention
Purpose of the present invention is exactly in order to solve the Chinese medicine cost height of present treatment heart failure, and problem such as effect is general, and toxic and side effects is strong provides that a kind of to have a cost low, the Chinese medicinal capsule of the treatment heart failure of advantage such as toxic and side effects is little, and therapeutic effect is good.
For achieving the above object, the present invention has adopted following technical scheme:
A kind of Chinese medicinal capsule for the treatment of heart failure, it is made up of following ingredients, and the weight portion of each composition is, LISHEN 5-7 part Fructus Schisandrae Chinensis 2-4 part 11-13 Radix Ophiopogonis part Radix Notoginseng 2-4 part Radix Aconiti Lateralis Preparata 2-4 part Herba Leonuri 14-16 part, mentioned component is pulverized last, crosses 200 mesh sieves, goes into capsule.
Described each composition weight portion is,
14 parts of 2 parts of Herba Leonuris of 5 parts of Fructus Schisandrae Chinensis of LISHEN, 2 parts of Radix Aconiti Lateralis Preparatas of 11 portions of Radix Notoginseng, 2 parts of Radix Ophiopogonis.
Described each composition weight portion is,
16 parts of 4 parts of Herba Leonuris of 7 parts of Fructus Schisandrae Chinensis of LISHEN, 4 parts of Radix Aconiti Lateralis Preparatas of 13 portions of Radix Notoginseng, 4 parts of Radix Ophiopogonis.
Described each composition weight portion is,
15 parts of 3 parts of Herba Leonuris of 6 parts of Fructus Schisandrae Chinensis of LISHEN, 3 parts of Radix Aconiti Lateralis Preparatas of 12 portions of Radix Notoginseng, 3 parts of Radix Ophiopogonis.
Heart failure especially gerontal patient's cardiac muscle is in blood or the under-supply state of energy, excessively or the prolonged application positive inotropic medicament with the imbalance between supply and demand of expend energy, make cardiac damage even more serious, and cause mortality rate to increase, even the Folium Digitalis Purpureae of existing 200 years applicating histories can improve the symptom of heart failure, therefore but its effective percentage is lower, and the long-term results that studies have shown that it of large sample can not reduce mortality rate, is not enough by positive inotropic medicament merely all in all from heart failure.The traditional Chinese medical science thinks that old heart failure is based on heart deficiency of kidney-QI weakened YANG QI.Its pathology three elements are empty, and the stasis of blood and diseases caused by retention of fluid are basis with the heart-yang deficiency of vital energy wherein, and blood stasis causing water retention is mark.So control and should consolidate by the QI invigorating warming YANG, the double blood diuretic of controlling is to take stopgap measures.LISHEN in the side, the Radix Aconiti Lateralis Preparata strongly invigorating primordial QI, the spleen invigorating of nourishing heart, the warming YANG activating QI, Herba Leonuri, pseudo-ginseng blood-circulation-invigovating removing blood stasis with potent drugs collateral dredging, Radix Ophiopogonis, the Fructus Schisandrae Chinensis tonifying YIN can be prevented the fraud that warm life is dry again with treating YANG within YIN, and all medicines share, and the motive must be mended, and heart-yang must help, and anhydrating of stasis of blood heart arteries and veins must be answered.
Modern pharmacological research is found, Radix Ginseng energy stimulating central nervous system, increase adrenal cortex function, improve the resistance of the pessimal stimulation to external world of body, antifatigue effect is by force arranged, can significantly improve the hypoxia-bearing capability of animal Radix Ophiopogonis, coronary blood flow increasing, heart throughput rate, expansion peripheral blood vessel, Fructus Schisandrae Chinensis, can regulate central nervous excitation and process of inhibition, strengthen cardiac contractility ability, breathing is had excitation, all medicine associatings, mainly influence sodium-potassium and Sodium exchange by the activity that suppresses smooth muscle cell sodium-potassium ATP enzyme, the interior stream of calcium is increased, promote the increase of calcium contractile protein exposure concentration, increase the contractility of cardiac muscle and diaphram.Has the effect of cardiotonic glycoside sample.Can stablize myocardial excitability and get nourishing yin effect Radix Ophiopogonis, play the effect of control arrhythmia.In addition, this medicine can improve animal to anoxybiotic tolerance and anoxia myocardial cell glycogen content, the content of RNA and DNA in the increase cardiac muscle, and then promote mitochondrion synthetic, increase energy, cardiac output and throughput rate are increased, shorten left chamber diastolic time, make the pressure load of depleted cardiac muscle, the mechanical pressure that volume load causes reduces.Lower myocardial oxygen consumption, obviously raising is whenever fought output, and the left ventricular ejection function is taken a turn for the better.Strengthen myocardial contraction, improve cardiac function, coronary blood flow increasing and raising cardiac index are improved cardiac function enduringly thereby reach, boost, pressure stabilization function is saved vitality, health invigorating, the quality of making the life better has played the purpose for the treatment of both the principal and secondary aspects of a disease, obtains promising result.
Clinical data: according to Fram inghan diagnostic criteria, include case 272 examples in, wherein male 177 examples, year mean age (68.97 ± 6.3); Woman's 95 examples, mean age (77.87 ± 9.4) year.The cause of disease comprises coronary heart disease 135 examples, hypertensive heart disease 91 examples, and chronic pulmonary heart disease 15 examples, rheumatic heart disease 6 examples are divided into treatment group 136 examples and matched group 136 examples at random.Physical data no difference of science of statistics such as its age, sex.
Therapeutic Method: two groups of patients all adopt the ELASA method to measure blood plasma BNP level before treatment.Treatment organize to Radix Ginseng 12g, Radix Ophiopogonis 12g, Fructus Schisandrae Chinensis 6g, Radix Notoginseng 3g, Radix Aconiti Lateralis Preparata 6g, decocting 200ml sooner or later each 100ml are oral, totally 21 days.Matched group gives diuresis cardiac tonic symptomatic treatment, and ACEI, beta-blocker or look the state of an illness and give the treatment of quiet FDP, meglumine adenosine cycle phosphate, and after 21 days, two groups of patients in kind measure blood plasma BNP level and clinical symptoms, compare observation.
Each organizes numerical value, and all (x ± s) expression, two groups of means relatively adopt the t check with mean ± standard deviation.Total data adopts the SPSS10.0 statistical software to handle, and there is statistical significance P＜0.05 for difference.
Criterion of therapeutical effect: the standard that diagnosis is formulated with reference to " Revision Principle is instructed in the new Chinese medicine clinical research " of Ministry of Public Health issue in 1993.Curative effect: treatment back transference cure, it is produce effects that cardiac function improves 2 grades or 3 grades; Sx, it is effective that cardiac function improves 1 grade; Cardiac function improves 1 grade of less than or worsens to invalid.
The result:
Two groups of patient treatment results relatively
Annotate: compare P＜0.05 between two groups
The BNP concentration ratio before and after two groups of treatments
Annotate: compare P＜0.05 between two groups.
The invention has the beneficial effects as follows: prescription is simple, and cost is low, and therapeutic effect is good.
The specific embodiment
The invention will be further described below in conjunction with the specific embodiment.
Embodiment 1:
14 parts of 2 parts of Herba Leonuris of power taking 5 parts of Fructus Schisandrae Chinensis 2 parts of Radix Aconiti Lateralis Preparatas of 11 portions of Radix Notoginseng, 2 parts of Radix Ophiopogonis of ginseng, each composition grinds the back and crosses 200 mesh sieves, goes into capsule and gets final product.
Embodiment 2:
Its each composition is as follows by weight, 16 parts of 4 parts of Herba Leonuris of 7 parts of Fructus Schisandrae Chinensis of LISHEN, 4 parts of Radix Aconiti Lateralis Preparatas of 13 portions of Radix Notoginseng, 4 parts of Radix Ophiopogonis.
All the other are identical with embodiment 1, repeat no more.
Embodiment 3:
Each composition is as follows by weight, 15 parts of 3 parts of Herba Leonuris of 6 parts of Fructus Schisandrae Chinensis of LISHEN, 3 parts of Radix Aconiti Lateralis Preparatas of 12 portions of Radix Notoginseng, 3 parts of Radix Ophiopogonis.
All the other are identical with embodiment 1, repeat no more.
Claims (4)
1, a kind of Chinese medicinal capsule for the treatment of heart failure, it is characterized in that: it is made up of following ingredients, and the weight portion of each composition is LISHEN 5-7 part Fructus Schisandrae Chinensis 2-4 part 11-13 Radix Ophiopogonis part Radix Notoginseng 2-4 part Radix Aconiti Lateralis Preparata 2-4 part Herba Leonuri 14-16 part, each component last mistake 200 mesh sieves of pulverizing are gone into capsule and are got final product.
2, the Chinese medicinal capsule of treatment heart failure according to claim 1 is characterized in that: described each composition weight portion is 14 parts of 2 parts of Herba Leonuris of 5 parts of Fructus Schisandrae Chinensis of LISHEN, 2 parts of Radix Aconiti Lateralis Preparatas of 11 portions of Radix Notoginseng, 2 parts of Radix Ophiopogonis.
3, the Chinese medicinal capsule of treatment heart failure according to claim 1 is characterized in that: described each composition weight portion is 16 parts of 4 parts of Herba Leonuris of 7 parts of Fructus Schisandrae Chinensis of LISHEN, 4 parts of Radix Aconiti Lateralis Preparatas of 13 portions of Radix Notoginseng, 4 parts of Radix Ophiopogonis.
4, the Chinese medicinal capsule of treatment heart failure according to claim 1 is characterized in that: described each composition weight portion is 15 parts of 3 parts of Herba Leonuris of 6 parts of Fructus Schisandrae Chinensis of LISHEN, 3 parts of Radix Aconiti Lateralis Preparatas of 12 portions of Radix Notoginseng, 3 parts of Radix Ophiopogonis.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2007100131188A CN100558387C (en) | 2007-01-10 | 2007-01-10 | The Chinese medicinal capsule of treatment heart failure |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2007100131188A CN100558387C (en) | 2007-01-10 | 2007-01-10 | The Chinese medicinal capsule of treatment heart failure |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN100998756A CN100998756A (en) | 2007-07-18 |
| CN100558387C true CN100558387C (en) | 2009-11-11 |
Family
ID=38257628
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2007100131188A Expired - Fee Related CN100558387C (en) | 2007-01-10 | 2007-01-10 | The Chinese medicinal capsule of treatment heart failure |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100558387C (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106421408A (en) * | 2016-12-15 | 2017-02-22 | 同溢堂药业有限公司 | Pharmaceutical composition for treating refractory heart failure |
| CN106880826A (en) * | 2017-03-15 | 2017-06-23 | 付蓉 | A kind of Chinese medicine preparation of chronic heart failure and preparation method thereof |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1305844A (en) * | 2001-01-14 | 2001-08-01 | 刘红 | Medicine for treating congestive heart failure |
-
2007
- 2007-01-10 CN CNB2007100131188A patent/CN100558387C/en not_active Expired - Fee Related
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1305844A (en) * | 2001-01-14 | 2001-08-01 | 刘红 | Medicine for treating congestive heart failure |
Non-Patent Citations (2)
| Title |
|---|
| 生脉散加味临床验案三例. 黄中柱.江西中医药，第3期. 1983 |
| 生脉散加味临床验案三例. 黄中柱.江西中医药，第3期. 1983 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN100998756A (en) | 2007-07-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103202879A (en) | Traditional Chinese medicine composition for treating chronic cardiac failure and preparation method thereof | |
| CN100418553C (en) | Preparation for treating osteoporosis and preparation method thereof | |
| CN100558387C (en) | The Chinese medicinal capsule of treatment heart failure | |
| CN103610936B (en) | A kind of Chinese medicine preparation and preparation method for the treatment of coronary heart disease | |
| CN103007159B (en) | Chinese medicinal preparation for correcting pancreas islet function | |
| CN100558388C (en) | A kind of Chinese medicine composition of orally taken for curing viral myocarditis | |
| CN102343049B (en) | Chinese medicinal capsules for treating hypertension due to liver-yang hyperactivity | |
| CN101195003B (en) | Proprietary Chinese medicine for treating apoplexy and sequela | |
| CN102988747B (en) | Aristida triseta electuary for reducing hypertension, hyperglycemia and hyperlipidemia and preparation method thereof | |
| CN102935214B (en) | Traditional Chinese medicinal composition for treating uremia | |
| CN102552677B (en) | Coptis chinensis and radix rehmanniae Anxiao capsule and preparation method thereof | |
| CN102526614B (en) | Chinese medicinal kidney healing powder for treating chronic renal failure | |
| CN100404056C (en) | Medicine for treating renal incompetence | |
| CN100398123C (en) | Medicine for treating diabetes of blood stasis complicated kidney spleen deficiency type | |
| CN102836353B (en) | Chinese medicine for treating diabetes | |
| CN102380017A (en) | Medicament for treating diabetes and preparation method of medicament | |
| CN108126008A (en) | Rosemary cordyceps sinensis ball | |
| CN102784296A (en) | Fructus trichosanthis oral liquid | |
| CN107669836A (en) | Coronary disease and angina pectoris Chinese medicine preparation and preparation method thereof | |
| CN1247237C (en) | Medicinal composition for treating coronary disease and its preparation and application | |
| CN105535852A (en) | Traditional Chinese medicine preparation for treating arrhythmia | |
| CN105288143A (en) | Traditional Chinese medicine composition for treating asthma | |
| CN104958504A (en) | Traditional Chinese medicine composition for preventing and treating sub-health and preparation method of traditional Chinese medicine composition | |
| CN1823890B (en) | Formula of oral Chinese medicine used for treating virus myocarditis | |
| CN104189424A (en) | Traditional Chinese medicine composition for treating heart failure |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20091111 Termination date: 20150110 |
|
| EXPY | Termination of patent right or utility model |